President of Breast Imaging Specialists Joins Clinical Advisory Board of First Warning Systems, Inc.

Reno, NV-based First Warning Systems, Inc. (FWS), a life sciences, wearable body media and large data company, recently welcomed Bonnie M. Rush, RT to the company’s Clinical Advisory Board. Rush brings more than 25 years of expertise in breast health to FWS, a company producing a non-invasive, intelligent, wearable, biofeedback early breast cancer-screening device. The addition of Rush to the Board brings another superior voice the FWS global mix of experts.

Rush currently serves as president for Breast Imaging Specialists of San Diego, Calif., providing education, in-services, clinical practice management, regulatory compliance and outreach programs to the breast imaging community. She established the first low-cost mammography screening program in San Diego and helped launch the San Diego Breast Cancer Early Detection Program. A long-time expert in the breast health field, Rush also authored the definitive explanation of the Mammography Quality Standards Act. Currently she serves as the AHRA (Association of Hospital Radiology Administrators) liaison to the Are You Dense Advocacy, Inc. to advance the cause of early detection for women with dense breasts.

First Warning Systems CEO Rob Royea says that Rush’s dedication to the advancement of women’s health and early breast cancer detection positions her to bring a compassionate, intelligent viewpoint to the FWS Clinical Advisory Board, a critical ingredient in the progression of the FWS technology. Her deep involvement in the advancement of breast health and proper early cancer detection over the years adds to the recent positive developments FWS has seen in the last few months. The company recently announced the retention of Joshua D.I. Ellenhorn, M.D., as principal investigator in preparation of impending clinical validation studies. FWS also secured Triple Ring Technologies as product developer.

With extensive clinical trials, and years of advanced algorithm refinement completed, FWS’ patented intelligent predictive models are projected to improve accuracy for breast cancer assessment to over 75 percent, according to the company.